Andreas Rimner

TL;DR: SBRT has an important role to play in treating early-stage NSCLC, particularly for medically inoperable patients with limited other treatment options, and shared decision-making with patients should be performed to ensure the patient understands the risks related to SBRT, the side effects, and the alternative treatments available.

TL;DR: These updated, exploratory analyses demonstrate durable PFS and sustained OS benefit with durvalumab following CRT, and are consistent with the primary analyses.

TL;DR: Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma.

TL;DR: EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy are amenable to local therapy to treat oligometastatic disease when used in conjunction with continued EGFR inhibition.

TL;DR: The authors used genome-wide analysis to examine methylome signatures in breast cancers with various metastatic behaviors and found a signature that was associated with low metastatic risk and improved rates of survival and significantly enhance the understanding of breast cancer oncogenesis and aid the development of new prognostic biomarkers.